Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03364686 · ClinicalTrials.gov registry record · Phase 2
Transfusion of Biotin-Labeled Red Blood Cells
A Phase 2 study, sponsored by Gladwin, Mark, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03364686: Clinical Trial Phase 2 study, sponsored by Gladwin, Mark, MD.
NCT03364686 is a Phase 2 study that was terminated before completion, run by Gladwin, Mark, MD. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03364686, a Phase 2 study, was terminated before completion, sponsored by Gladwin, Mark, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the impact of genetic and biologic factors in blood donors on red blood cell storage stability after autologous transfusion over the different range of storage period of 5-7 days and 35-42 days in healthy volunteers.
Primary Outcome
This will be determined using enumeration of biotinylated red blood cells obtained by flow cytometry from blood samples obtained at various time points from subjects with specified genetic mutations, compared with control subjects without the specified mutation. Percentage of Biotin Labeled Red Blood Cells is determined by Biotin Labeled Red Blood Cells in circulation at each time point/baseline Biotin Labeled Red Blood Cells in circulation x 100.
Interventions
- BIOLOGICAL Biotin-Labeled Red Blood Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 2 |
Why NCT03364686 stopped before completion
NCT03364686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Biotin-Labeled Red Blood Cells is the first listed.
NCT03364686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03364686 about?
NCT03364686 is a clinical study titled "Transfusion of Biotin-Labeled Red Blood Cells". The purpose of this research is to evaluate the impact of genetic and biologic factors in blood donors on red blood cell storage stability after autologous transfusion over the different range of storage period of 5-7 days and 35-42 days in healthy volunteers.
What is the current status of trial NCT03364686?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-09-16. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT03364686?
The interventions under investigation include: Biotin-Labeled Red Blood Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03364686?
This trial is sponsored by Gladwin, Mark, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03364686's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI